In this partnership PolarisQB will be working with Auransa to target endometriosis, polycystic ovary syndrome, triple negative breast cancer and ovarian cancer, searching for molecules that may be used to treat these conditions that affect women almost exclusively and have been neglected by modern pharmaceutical research. They will be using the Tachyon system PolarisQB has developed, which utilizes quantum computing to simulate the quantum nature of chemical interactions, leading to much faster lead prediction when researching molecular treatments for anything from Dengue Fever to Alzheimers. Auransa has developed a data and AI-driven platform capable of ingesting complex human disease data, large and small, and use that data to understand the biology of complex diseases. They will use their SMarTR Engine to study molecular disease subtypes and predict compounds and targets for responder patient populations. For additional information, you can view a news release located on the PolarisQB website here.
June 4, 2021
